US 12,227,567 B2
Treating cancer by blocking the interaction of TIM-3 and its ligand
Dongxu Sun, Los Altos, CA (US); and Yan Wang, Concord, CA (US)
Assigned to TrueBinding, Inc., Menlo Park, CA (US)
Appl. No. 16/633,530
Filed by TRUEBINDING, INC, Foster City, CA (US)
PCT Filed Jul. 24, 2018, PCT No. PCT/US2018/043513
§ 371(c)(1), (2) Date Jan. 23, 2020,
PCT Pub. No. WO2019/023247, PCT Pub. Date Jan. 31, 2019.
Claims priority of provisional application 62/536,886, filed on Jul. 25, 2017.
Prior Publication US 2020/0223921 A1, Jul. 16, 2020
Int. Cl. A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 9/0019 (2013.01); A61P 35/04 (2018.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/30 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01)] 15 Claims
 
1. A method of activating an immune response in a patient with a cancer, comprising:
administering to the patient an effective amount of an anti-Gal3 antibody that interferes with the interaction between Gal3 and TIM-3, wherein the anti-Gal3 antibody comprises
(1) a light chain variable region comprising a complementary determining region (CDR) L1, a CDR L2, and a CDR L3 and
(2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3,
wherein
the CDR L1 comprises the amino acid sequence of SEQ ID NO:17,
the CDR L2 comprises the amino acid sequence of SEQ ID NO:18,
the CDR L3 comprises the amino acid sequence of SEQ ID NO:19,
the CDR H1 comprises the amino acid sequence of SEQ ID NO:9,
the CDR H2 comprises the amino acid of SEQ ID NO:10, and
the CDR H3 comprises the amino acid sequence of SEQ ID NO:11;
wherein the Gal3 is overexpressed on cells in a tumor microenvironment,
the TIM-3 is expressed on immune cells, and
the effective amount is sufficient to activate the immune response in the patient
wherein the anti-Gal3 antibody is a humanized antibody or a human antibody.